FDA Approves First Therapy for Patients with RET Mutation Non-small cell lung cancer

[Miranda_GO2]

More exciting news in the lung cancer community: treatment for non-small cell lung cancer, stage IV, with RET mutation approved.

"Today, the U.S. Food and Drug Administration approved Retevmo (selpercatinib) capsules to treat three types of tumors – non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers – in patients whose tumors have an alteration (mutation or fusion) in a specific gene (RET or “rearranged during transfection”). Retevmo is the first therapy approved specifically for cancer patients with the RET gene alterations...."

Read more about the FDA approval at this link: fda.gov/news-events/press-a...